Shanghai Junshi Biosciences Co (FRA:8SJ) Net Income From Continuing Operations : €-177.8 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shanghai Junshi Biosciences Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shanghai Junshi Biosciences Co's net income from continuing operations for the three months ended in Dec. 2024 was €-51.5 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was €-177.8 Mil.

Shanghai Junshi Biosciences Co Net Income From Continuing Operations Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Net Income From Continuing Operations Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-209.85

-82.35

-362.24

-319.77

-178.26

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-125.70	-38.28	-49.79	-38.24	-51.53

Shanghai Junshi Biosciences Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-177.8 Mil.

Shanghai Junshi Biosciences Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (FRA:8SJ) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

01877:Hong Kong 688180:China

Address

No. 987 Cai Lun Road, Level 4, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group's operations are mainly located in the PRC and the United States of America.

Shanghai Junshi Biosciences Co Headlines

No Headlines